title: Spinal cord transient ischemic attacks: a possible role for abciximab.
authors.affiliation: Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Muhammad S
authors.initials: MS
authors.lastname: Hussain
authors.forename: Ashfaq
authors.initials: A
authors.lastname: Shuaib
authors.forename: Zaeem A
authors.initials: ZA
authors.lastname: Siddiqi
mesh_terms: D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D001012:Aorta, Abdominal / Q000601:surgery; D001018:Aortic Diseases / Q000150:complications; D002114:Calcinosis / Q000150:complications; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005263:Femoral Artery / Q000601:surgery; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D007511:Ischemia / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D012678:Sensation Disorders / Q000188:drug therapy / Q000209:etiology; D013116:Spinal Cord / Q000098:blood supply*; D013927:Thrombosis / Q000150:complications / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000188:drug therapy / Q000209:etiology; D014859:Warfarin / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D006493:Heparin; D000077284:Abciximab